Managing low-grade dysplasia

Aelaf D. Worku, Thomas A. Ullman

Research output: Contribution to journalReview article

Abstract

The known colitis-dysplasia-carcinoma sequence allows for gastroenterologist-endoscopists to identify early neoplastic changes and perform maneuvers that will result in improved outcomes for patients. The key maneuvers that can lead to improved cancer-free survival are, firstly, endoscopic removal of dysplasia using standard polypectomy techniques; and, secondly, timely colectomy for patients with insufficiently resected dysplasia. Inadequately described molecular and genetic pathways allow for a more rapid progression of colitis to dysplasia than that described in noncolitis mucosa. Additionally, such progression, in the face of inflamed mucosa, can be difficult to detect and obfuscated to the eye of an endoscopist. As optics continue to improve and endoscopic adjuncts - principally chromoendoscopy with methylene blue or indigo carmine - have been developed, we have the ability to better identify and remove dysplastic lesions from patients with colitis. Thus, while we have the opportunity to change the natural history of low-grade dysplasia (LGD), we must proceed with caution in patients in whom an identifiable lesion is incompletely identified or resected. Patients in whom no specific lesion from which LGD is identified or resected harbor an approximate 20% risk of already having a cancer, and should be referred for colectomy. Patients in whom lesions are identified and removed may continue undergoing surveillance, but should be followed more closely with colonoscopic evaluation every 6 months using scopes and scope systems with the best available optics and chromoendoscopic techniques. This article reviews the available evidence supporting these recommendations.

Original languageEnglish (US)
Pages (from-to)1-6
Number of pages6
JournalInflammatory Bowel Disease Monitor
Volume11
Issue number1
StatePublished - Dec 1 2010
Externally publishedYes

Fingerprint

Colitis
Colectomy
Mucous Membrane
Indigo Carmine
Methylene Blue
Natural History
Molecular Biology
Neoplasms
Carcinoma
Survival

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Managing low-grade dysplasia. / Worku, Aelaf D.; Ullman, Thomas A.

In: Inflammatory Bowel Disease Monitor, Vol. 11, No. 1, 01.12.2010, p. 1-6.

Research output: Contribution to journalReview article

Worku, Aelaf D. ; Ullman, Thomas A. / Managing low-grade dysplasia. In: Inflammatory Bowel Disease Monitor. 2010 ; Vol. 11, No. 1. pp. 1-6.
@article{1353ca981e1c417bb52d1ba96d7aa265,
title = "Managing low-grade dysplasia",
abstract = "The known colitis-dysplasia-carcinoma sequence allows for gastroenterologist-endoscopists to identify early neoplastic changes and perform maneuvers that will result in improved outcomes for patients. The key maneuvers that can lead to improved cancer-free survival are, firstly, endoscopic removal of dysplasia using standard polypectomy techniques; and, secondly, timely colectomy for patients with insufficiently resected dysplasia. Inadequately described molecular and genetic pathways allow for a more rapid progression of colitis to dysplasia than that described in noncolitis mucosa. Additionally, such progression, in the face of inflamed mucosa, can be difficult to detect and obfuscated to the eye of an endoscopist. As optics continue to improve and endoscopic adjuncts - principally chromoendoscopy with methylene blue or indigo carmine - have been developed, we have the ability to better identify and remove dysplastic lesions from patients with colitis. Thus, while we have the opportunity to change the natural history of low-grade dysplasia (LGD), we must proceed with caution in patients in whom an identifiable lesion is incompletely identified or resected. Patients in whom no specific lesion from which LGD is identified or resected harbor an approximate 20{\%} risk of already having a cancer, and should be referred for colectomy. Patients in whom lesions are identified and removed may continue undergoing surveillance, but should be followed more closely with colonoscopic evaluation every 6 months using scopes and scope systems with the best available optics and chromoendoscopic techniques. This article reviews the available evidence supporting these recommendations.",
author = "Worku, {Aelaf D.} and Ullman, {Thomas A.}",
year = "2010",
month = "12",
day = "1",
language = "English (US)",
volume = "11",
pages = "1--6",
journal = "Inflammatory Bowel Disease Monitor",
issn = "1466-7401",
publisher = "Remedica Medical Education and Publishing Ltd",
number = "1",

}

TY - JOUR

T1 - Managing low-grade dysplasia

AU - Worku, Aelaf D.

AU - Ullman, Thomas A.

PY - 2010/12/1

Y1 - 2010/12/1

N2 - The known colitis-dysplasia-carcinoma sequence allows for gastroenterologist-endoscopists to identify early neoplastic changes and perform maneuvers that will result in improved outcomes for patients. The key maneuvers that can lead to improved cancer-free survival are, firstly, endoscopic removal of dysplasia using standard polypectomy techniques; and, secondly, timely colectomy for patients with insufficiently resected dysplasia. Inadequately described molecular and genetic pathways allow for a more rapid progression of colitis to dysplasia than that described in noncolitis mucosa. Additionally, such progression, in the face of inflamed mucosa, can be difficult to detect and obfuscated to the eye of an endoscopist. As optics continue to improve and endoscopic adjuncts - principally chromoendoscopy with methylene blue or indigo carmine - have been developed, we have the ability to better identify and remove dysplastic lesions from patients with colitis. Thus, while we have the opportunity to change the natural history of low-grade dysplasia (LGD), we must proceed with caution in patients in whom an identifiable lesion is incompletely identified or resected. Patients in whom no specific lesion from which LGD is identified or resected harbor an approximate 20% risk of already having a cancer, and should be referred for colectomy. Patients in whom lesions are identified and removed may continue undergoing surveillance, but should be followed more closely with colonoscopic evaluation every 6 months using scopes and scope systems with the best available optics and chromoendoscopic techniques. This article reviews the available evidence supporting these recommendations.

AB - The known colitis-dysplasia-carcinoma sequence allows for gastroenterologist-endoscopists to identify early neoplastic changes and perform maneuvers that will result in improved outcomes for patients. The key maneuvers that can lead to improved cancer-free survival are, firstly, endoscopic removal of dysplasia using standard polypectomy techniques; and, secondly, timely colectomy for patients with insufficiently resected dysplasia. Inadequately described molecular and genetic pathways allow for a more rapid progression of colitis to dysplasia than that described in noncolitis mucosa. Additionally, such progression, in the face of inflamed mucosa, can be difficult to detect and obfuscated to the eye of an endoscopist. As optics continue to improve and endoscopic adjuncts - principally chromoendoscopy with methylene blue or indigo carmine - have been developed, we have the ability to better identify and remove dysplastic lesions from patients with colitis. Thus, while we have the opportunity to change the natural history of low-grade dysplasia (LGD), we must proceed with caution in patients in whom an identifiable lesion is incompletely identified or resected. Patients in whom no specific lesion from which LGD is identified or resected harbor an approximate 20% risk of already having a cancer, and should be referred for colectomy. Patients in whom lesions are identified and removed may continue undergoing surveillance, but should be followed more closely with colonoscopic evaluation every 6 months using scopes and scope systems with the best available optics and chromoendoscopic techniques. This article reviews the available evidence supporting these recommendations.

UR - http://www.scopus.com/inward/record.url?scp=84863848688&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863848688&partnerID=8YFLogxK

M3 - Review article

AN - SCOPUS:84863848688

VL - 11

SP - 1

EP - 6

JO - Inflammatory Bowel Disease Monitor

JF - Inflammatory Bowel Disease Monitor

SN - 1466-7401

IS - 1

ER -